This is an randomized trial to evaluate the potential benefit of erythropoietin in the treatment of anemia in patients with lymphoma after autologous hematopoietic stem cell transplantation.
Lymphoma patients with anemia on day +15 post-transplant will be randomized to erythropoietin group or control group. Potential benefit of erythropoietin will be evaluatedon day +60 post-transplant.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Enrollment
70
Erythropoietin will be administered subcutaneously (s.c.) at the dose of 10 000 IU, three times a week. If necessary,oral ferrous succinate vitamins B12 and folic acid will be administered.
If necessary, oral ferrous succinate, vitamins B12 and folic acid will be administered.
Peking University Cancer Hospital & Institute
Beijing, Beijing Municipality, China
RECRUITINGcomplete hemoglobin response rate
proportion of complete correctors (reaching hemoglobin 120 g/L in male patients, 110 g/L in female patients) before day +60 post-transplant
Time frame: from day +15 to day +60 after autologous hematopoietic stem cell transplantation
proportion of participants with red blood cell transfusions
proportion of participants with red blood cell transfusions from day +15 to day +60 post-transplant
Time frame: from day +15 to day +60 after autologous hematopoietic stem cell transplantation
proportion of participants with deep vein thrombosis
proportion of participants with deep vein thrombosis from day +15 to day +60 post-transplant
Time frame: from day +15 to day +60 after autologous hematopoietic stem cell transplantation
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.